Nasus Pharma (NSRX) announced the successful initiation of the Company’s Phase 2 clinical study with dosing of the first participant in Canada. The trial aims to evaluate NS002, the Company’s investigational intranasal epinephrine powder formulation, compared to EpiPen for the treatment of anaphylaxis. NS002 could potentially offer patients a needle-free alternative to traditional epinephrine autoinjectors. Interim results from this trial are expected in the first quarter of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRX:
- Nasus Pharma Initiates Phase 2 Study of Needle-Free Epinephrine
- Nasus Pharma approved by Health Canada to start Phase 2 study of NS002
- Nasus Pharma Updates Corporate Presentation
- Nasus Pharma participates in conference call hosted by Citizens JMP
- Nasus Pharma’s Innovative Approach to Anaphylaxis Treatment: A Clinical Study Update